Synchron Lab Automation has co-developed with Bayer Health Care an platform for the automation of transient protein expression in mammalian cells for the production of proteins. The platform significant increase in biologics R&D productivity by the implementation of an automated process for the transient expression of therapeutic monoclonal antibodies and tool-proteins within Bayer’s existing infrastructure and R&D processes.
The concept of the automation for the transient expression of proteins is based on an automated platform combining the transfection of mammalian cells, a supplementation and analysis tool (viable cell density/ml, cell viability, productivity mg/L) and a unique harvesting step of expressed proteins via centrifugation and filtration for downstream purification and further characterization. The availability of sufficient amounts of proteins, like therapeutic monoclonal antibodies or Fc-fusion proteins, is a prerequisite for their further characterization and optimization within biopharmaceutical research and development.
An automated platform for the transient expression of recombinant proteins in a mammalian cell line has been established successfully in order to increase throughput and reduce development time. The cell line used for transient expression is a human embryonic kidney 293 cell line (HEK293-6E, Durocher et al. 2002, Tom et al. 2007) grown in suspension, using 35 ml tube spins with vented lids. The transient transfection workstation is robust and reliable, resulting in protein production rates comparable to manually performed transient transfections. This is just one of the co-developed projects, for more information see
Synchron website or visit the booth at LabAutomation.
Register here for a visit.